GENinCode plc (GENI.L)
GENI.L Stock Price Chart
Explore GENinCode plc interactive price chart. Choose custom timeframes to analyze GENI.L price movements and trends.
GENI.L Company Profile
Discover essential business fundamentals and corporate details for GENinCode plc (GENI.L) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
22 Jul 2021
Employees
42.00
Website
https://www.genincode.comCEO
Matthew Heaton Walls
Description
GENinCode Plc engages in the development and commercialization of clinical genetic tests to provide predictive analysis of risk to a patient's health based on their genes in the United Kingdom and internationally. Its predictive technology provides patients and physicians with preventative care and treatment strategies. The company's molecular tests combine clinical algorithms and artificial intelligence to provide advanced patient risk assessment to predict disease onset. Its tests include Cardio inCode, a patented genetic test to help user to adopt cardiovascular prevention steps; Lipid inCode, a genetic diagnostic test, which analyzes the seven genes associated with familial hypercholesterolemia; SUDD inCode, a genetic test to diagnose the cause of sudden cardiac death and familial heart disease; Thrombo inCode, a genetic test that analyzes 12 genetic variants related to hereditary thrombophilia and the risk of thrombosis; and Thrombo inCode Reproductive Health, a genetic test that offers information related to risk of thrombophilia and associated risks for future pregnancies. GENinCode Plc was incorporated in 2018 and is based in Oxford, the United Kingdom.
GENI.L Financial Timeline
Browse a chronological timeline of GENinCode plc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 23 Sept 2025
Earnings released on 4 Jun 2025
EPS came in at -£0.01 surpassing the estimated -£0.02 by +24.97%, while revenue for the quarter reached £1.31M, missing expectations by -35.65%.
Earnings released on 25 Sept 2024
EPS came in at -£0.01, while revenue for the quarter reached £1.39M.
Earnings released on 3 Jun 2024
EPS came in at -£0.04 falling short of the estimated -£0.03 by -11.15%, while revenue for the quarter reached £1.21M, missing expectations by -74.58%.
Earnings released on 20 Sept 2023
EPS came in at -£0.04, while revenue for the quarter reached £950.00K.
Earnings released on 8 Jun 2023
EPS came in at -£0.03 falling short of the estimated -£0.03 by -4.07%, while revenue for the quarter reached £766.00K, missing expectations by -0.26%.
Earnings released on 30 Jun 2022
EPS came in at -£0.02, while revenue for the quarter reached £664.00K.
Earnings released on 31 Dec 2021
EPS came in at -£0.03, while revenue for the quarter reached £554.21K.
Earnings released on 30 Jun 2021
EPS came in at -£0.01, while revenue for the quarter reached £599.79K.
Earnings released on 31 Dec 2020
EPS came in at -£0.06, while revenue for the quarter reached £546.95K.
GENI.L Stock Performance
Access detailed GENI.L performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.